Lovenox is essentially the entire market for low-molecular-weight heparins—see #msg-44644009.
Presumably as long as Lovenox is around, PYMX's drug, with its ability to reverse it, stands to benefit. There seems to be a bit of margin of error in terms of success of PYMX's drug given the company's roughly $150M market cap (using fully-diluted shares of ~133M).
Market Data 
Markets 
AI
